Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment by 吏��뿄�쁺
ARTICLE
Mutations in six nephrosis genes delineate a
pathogenic pathway amenable to treatment
Shazia Ashraf et al.#
No efﬁcient treatment exists for nephrotic syndrome (NS), a frequent cause of chronic kidney
disease. Here we show mutations in six different genes (MAGI2, TNS2, DLC1, CDK20, ITSN1,
ITSN2) as causing NS in 17 families with partially treatment-sensitive NS (pTSNS). These
proteins interact and we delineate their roles in Rho-like small GTPase (RLSG) activity, and
demonstrate deﬁciency for mutants of pTSNS patients. We ﬁnd that CDK20 regulates DLC1.
Knockdown of MAGI2, DLC1, or CDK20 in cultured podocytes reduces migration rate.
Treatment with dexamethasone abolishes RhoA activation by knockdown of DLC1 or CDK20
indicating that steroid treatment in patients with pTSNS and mutations in these genes is
mediated by this RLSG module. Furthermore, we discover ITSN1 and ITSN2 as podocytic
guanine nucleotide exchange factors for Cdc42. We generate Itsn2-L knockout mice that
recapitulate the mild NS phenotype. We, thus, deﬁne a functional network of RhoA regula-
tion, thereby revealing potential therapeutic targets.
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Nephrotic syndrome (NS) is the second most frequentcause of chronic kidney disease in the ﬁrst three decadesof life, requiring dialysis or transplantation for survival1.
Based on its response to steroid treatment, steroid sensitive NS
(SSNS) is distinguished from steroid resistant NS (SRNS). No
efﬁcient treatment for SRNS exists, and very little is known about
disease mechanisms. Mutations in more than 40 genes have been
identiﬁed as causing monogenic (single-gene) forms of NS.
Interestingly, most of the encoded gene products localize to renal
glomerular podocytes, conﬁrming that podocyte loss of function
is a critical part of the pathogenesis of NS and that any and all of
these proteins are important for the maintenance of glomerular
function2,3. These ﬁndings have thereby helped deﬁne protein
interaction complexes and functional pathways that could be
targeted for future potential treatment of NS2,4–7. In addition, the
mechanistic causes of steroid resistance have been a conundrum
for almost six decades of their use. So far, only one causative gene
(EMP2) has been discovered in SSNS8. We recently demonstrated
in a large cohort of 1780 families with SRNS that in about 30% of
individuals with SRNS a monogenic cause can be detected,
indicating that additional single gene causes of NS must exist that
are yet to be identiﬁed9.
Therefore by performing whole exome sequencing in indivi-
duals with partially treatment sensitive NS (pTSNS), we discover
six novel monogenic causes for pTSNS. Strikingly, all six encoded
proteins interacted within a functional module of podocytic
regulation of Rho-like small GTPase (RLSG) and are at the
intersection between steroid sensitivity vs. steroid resistance
of NS.
Results
Mutations in six novel genes cause NS in humans. To identify
additional genes mutated in NS we performed homozygosity
mapping (HM)10 combined with whole exome sequencing
(WES)11 in multiple families with NS. We also performed high-
throughput exon sequencing12,13 in a worldwide cohort of ~1000
additional families with NS, examining speciﬁc candidate genes
for NS based on genetic mouse models of NS.
Mice lackingMagi2 develop NS14–16. We sequenced allMAGI2
exons in 400 patients with NS. We identiﬁed homozygous
truncating mutations in the MAGI2 gene (p.Gly39* and p.
Tyr746*) in two individuals with SRNS and neurologic impair-
ment (Fig. 1a, b, Supplementary Table 1, Supplementary Fig. 1A).
p.Gly39* was detected in an affected individual of Arab descent.
p.Tyr746* was due to maternal isodisomy for chromosome 7. We
thereby discovered recessive MAGI2 mutations as a cause of
SRNS with neurologic involvement in humans (Fig. 2a). Very
recently, recessive mutations in MAGI2 in humans with NS have
been conﬁrmed17.
In individual A1358 of Turkish origin with early-onset NS and
histology of minimal change nephrotic syndrome (MCNS)
(Supplementary Table 1), HM yielded ten regions of homo-
zygosity by descent, none of which coincided with any of the
known recessive SRNS loci (Fig. 1c). By WES, we detected a novel
homozygous missense mutation (p. Arg292Gln) in the TNS2
(tensin-2) gene on chromosome 12q13.13 (Supplementary
Table 2). The mutation alters an amino acid residue conserved
throughout evolution from C. intestinalis on. Direct inspection of
sequence alignments did not yield a mutation in any of the 30
known SRNS genes3, and no additional homozygous truncating
mutations were detected in any other gene within the mapped
candidate regions. By high-throughput exon sequencing, we
detected in 4 additional families (A283, 2605, A3775, and A1640)
5 additional homozygous or compound heterozygous missense
mutations of TNS2 (Fig. 1d, Supplementary Table 1,
Supplementary Fig. 1B). The variant p.Ile858Met apparently
represents a founder allele from India (Supplementary Table 1).
Altered amino acid residues were well conserved throughout
evolution (Supplementary Table 1). We thereby discovered
recessive TNS2 mutations as a novel cause of NS (Fig. 2a). We
introduce the term “NPHS19” for this distinct entity of NS.
Because TNS2 protein is known to interact with DLC1 (deleted
in liver cancer 1)18,19, we hypothesized that mutations of DLC1
may also cause NS. By high-throughput exon sequencing, we
identiﬁed recessive mutations of DLC1 in 4 families with NS
(Supplementary Table 1). Speciﬁcally, in individual A548-21 with
FSGS, we detected two compound heterozygous mutations: p.
Trp10* and p.Ser43Thr. In an individual of Arab descent (A4967-
21) with SRNS and a biopsy showing focal segmental glomerulo-
sclerosis (FSGS) (Fig. 1e), we identiﬁed two compound hetero-
zygous mutations, p.Glu180Ala and p.Lys1358Thr, in DLC1
(Fig. 1f, Supplementary Table 1, Supplementary Fig. 1C). In an
affected individual from Asia (A3118-21), we detected a
homozygous mutation (p.Ala456Val) in exon 6 of DLC1 with
amino acid conservation since C.elegans (Fig. 1f, Supplemen-
tary Table 1, Supplementary Fig. 1C). In family 2706 we identiﬁed
a homozygous missense mutation (p.Ala1352Val) in exon 17 of
DLC1 (Fig. 1f, Supplementary Table 1). We thereby discovered
recessive DLC1 mutations as a novel cause of pTSNS (Fig. 2a).
We introduce the term “NPHS20” for this distinct entity of NS.
Interestingly, a distinct disease phenotype of partially treatment
sensitive nephrotic syndrome (pTSNS) occurred in four of the
ﬁve individuals with recessive TNS2 and in two of the four
individuals with DLC1 mutations. pTSNS that mostly manifested
between 1 and 7 years of age, with the exception of A548-21 and
2706 where the onset of NS was in adulthood (Supplemen-
tary Table 1). Interestingly, these individuals showed complete or
partial response to prednisolone or cyclosporine A.
In family A5013 of Arab origin, an individual had pTSNS with
the unusual renal histology of membranoproliferative glomer-
ulonephritis (MPGN) (Fig. 1g). HM yielded 12 regions of
homozygosity by descent, none of which coincided with any of
the known recessive NS loci (Fig. 1h). By WES, we detected a
novel homozygous missense mutation (p.Phe204Leu) in exon 6 of
the CDK20 gene on chromosome 9q22.1, encoding “cyclin-
dependent kinase 20” (Fig. 1i, Supplementary Table 1, Supple-
mentary Table 2). The mutation alters an amino acid residue
conserved throughout evolution from C. elegans on (Supplemen-
tary Fig. 1D).
By HM and WES in two siblings of Arab family A3706 (Fig. 1j,
Supplementary Table 1, Supplementary Table 2) with early-onset
NS we identiﬁed a homozygous missense mutation of ITSN1
(Intersectin 1) at a highly conserved amino acid residue (p.
Pro180Ser). By high-throughput sequencing, we identiﬁed two
additional families (A977 and A2274) with four additional
compound heterozygous missense mutations of ITSN1 (Fig. 1k,
Supplementary Table 1, Supplementary Fig. 1E). Although the
mice lacking Itsn1 have been shown to exhibit a neuronal
phenotype20, none of individuals with early-onset NS identiﬁed
here showed any brain abnormalities. We introduce the term
“NPHS21” for this distinct entity of NS.
WES was also performed in ﬁve members of a Japanese family
(two patients and their unaffected members) (Supplementary
Fig. 2). Both affecteds in this family (Pat1, Pat 2) had pTSNS and
renal histology in both the siblings showed MCNS (Fig. 1l). By
WES, we identiﬁed two compound heterozygous mutations in
trans in ITSN2 (intersectin 2), a missense mutation (p.Ser339Cys)
in exon 11 and a frame-shift deletion (p.Ile1214Serfs*2) in exon
30 of ITSN2 (Fig. 1m, Supplementary Fig. 1F, Supplemen-
tary Table 1, Supplementary Table 3). Additionally, in an
individual from Arab with pTSNS (A3384), we detected a
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homozygous missense mutation (p.Glu438Gly) in exon 12 of
ITSN2 (Fig. 1m, Supplementary Table 1). We thereby discovered
recessive ITSN2 mutations as novel cause of pTSNS (Fig. 2a). We
introduce the term “NPHS22” for this distinct entity of NS.
Interestingly, all three patients (from two families) with ITSN2
mutations had pTSNS, as well as two out of four patients (from
three families) with ITSN1 mutations. Similar to patients with
TNS2, DLC1 or CDK20 mutations, most patients with ITSN2 or
ITSN1 mutations also showed partial or complete response to
Cyclosporine A.
For all mutations in all six genes segregation status was
compatible with recessive inheritance (Supplementary Table 1).
Supplementary Table 4 lists all the variant frequencies for all the
identiﬁed mutations in the Exome Aggregation Consortium
(ExaC) and the genome aggregation database (GnomAD) along
with their prediction scores using Mutation Taster (http://www.
mutationtaster.org/) and Polyphen 2 (http://genetics.bwh.
harvard.edu/pph2/) in silico tools. As a negative control, we
performed screening for all variants that we detected in the
pTSNS patients in an in-house cohort of exome data from 248
NPHP cases. This control did not reveal any homozygous carriers
(Supplementary Table 4).
Three of the six proteins interact with DLC1. We discovered
that four proteins MAGI2, TNS2, DLC1, and CDK20, in which
we detected recessive defects as novel causes of pTSNS, interact
physically or functionally to regulate RhoA/Rac1/Cdc42. Speciﬁ-
cally, we detected or conﬁrmed the following protein–protein
interactions:
First, because MAGI2 was known to interact with PTEN21, and
because TNS2 contains a PTEN domain (Figs 1d and 2a), we
hypothesized that MAGI2 may also interact with TNS2. By co-
overexpression and co-immunoprecipitation (coIP) of wildtype
and mutant cDNA clones in HEK293T cells, we found that
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MAGI2 in fact interacts with TNS2 (Fig. 2b), which we conﬁrmed
in a conﬁrmatory coIP (Supplementary Fig. 3A). Both mutant
MAGI2 constructs, Gly39* and Tyr746* that reﬂect alleles of NS
patients, A5146 and B91, respectively, abrogate this interaction
(Fig. 2a, b). The six mutations detected in TNS2 did not abrogate
interaction with MAGI2 (Supplementary Fig. 3B).
Second, MAGI2 also interacted with DLC1 (Fig. 2a, c). One
mutant MAGI2 construct Gly39* reﬂecting the mutation of NS
patient A5146 abrogates this interaction (Fig. 2c), as conﬁrmed in
a conﬁrmatory coIP (Supplementary Fig. 4).
Third, because TNS2 had been shown to interact with DLC119,
we performed coIP upon co-overexpression in HEK293T cells.
We conﬁrmed TNS2-DLC1 interaction (Fig. 2a), however, none
of the TNS2 or DLC1 missense mutations identiﬁed in NS
patients abrogated this interaction (Supplementary Fig. 5A, B).
Fourth, because we identiﬁed a CDK20 mutation in patient
A5013 with pTSNS, and because a related serine/threonine
protein kinase, CDK5, was shown to interact with DLC122, we
tested whether CDK20 would likewise interact with DLC1. By
coIP we show that in fact CDK20 interacts with DLC1 (Fig. 2a,d)
which we conﬁrmed in a coIP (Supplementary Fig. 6A). We
found that the clone reﬂecting DLC1 mutation Trp10* of
individual A548 abrogated this interaction (Supplementary
Fig. 6B). This interaction was conﬁrmed by half endogenous
Co-IPs in HEK293T cells (Supplementary Fig. 7A, B).
Finally, it was recently shown that the RhoGAP DLC1 interacts
with caveolin-1 (CAV1) via DLC1’s START domain23 (Fig. 2a),
and that CAV1 expression is regulated by EMP224 (Fig. 2a). This
regulation was shown to be steroid sensitive25. Furthermore, we
had shown that EMP2 mutations were the only monogenic cause
of SSNS known so far in humans8 as well as in a zebraﬁsh model
of SSNS25. To determine whether CAV1 could directly be
involved in DLC1 regulation, we performed coIP between DLC1
and CAV1 by co-overexpression in HEK293T cell. We conﬁrmed
that DLC1 interacts with CAV1 (Fig. 2a, e), and showed that the
mutant Lys1358Thr, reﬂecting the allele of NS patient A4967 and
present in CAV-1 binding site in DLC123, abrogated this
interaction (Fig. 2e). To further test the effect of steroids on this
interaction, we performed reciprocal coIP between co-
overexpressed DLC1 and CAV1 in HEK293T cells that were
pre- and post-treated with 100 uM of dexamethasone (Supple-
mentary Fig. 8). However, this treatment did not alter the results
shown in Fig. 2e. We demonstrated by co-overexpression in
HEK293T cells that CAV1 also interacts with TNS2 and MAGI2
(Supplementary Fig. 9A, B).
In summary, we identiﬁed in patients with pTSNS recessive
mutations in six different genes, the products of which mutually
interact within a complex that contains the RhoGAP DLC1. The
ﬁnding that speciﬁc mutations abrogated some of these interac-
tions most likely reﬂects allele-speciﬁc pathogenic effects of these
mutations.
Furthermore, we also investigated the endogenous expression
of TNS2 and DLC1 by immunoﬂuorescence microscopy (IF) in
human podocytes and found that both TNS2 and DLC1
colocalize with an antibody labeling phosphotyrosine at focal
and ﬁbrillar adhesions, consistent with the role of focal adhesions
in podocyte migration26 and the pathogenesis of NS27,28
(Supplementary Fig. 10). Additionally, by IF we show that upon
overexpression, full length GFP-MAGI2 colocalizes with β-
catenin at adherens junctions. In contrast, overexpression of
GFP-MAGI2 Gly39* and Tyr746*, representing mutations in
pTSNS, fail to localize at adherens junctions (Supplementary
Fig. 11).
Circular dichroism modeling of mutation in SAM domain of
DLC1. Since one of the mutations (p.Ala456Val) in DLC1 is
located in its SAM domain, we studied effect of this mutation on
its secondary structure by performing circular dichroism (CD)
assay. The wild type (WT) and mutant (Ala19Val in SAM
domain) proteins did not show any difference in their CD
spectrum indicating overall similar three dimensional fold (Sup-
plementary Fig. 12A). We then recorded the melting spectrum of
WT and mutant proteins and found that the denaturation tem-
perature of WT SAM domain was near to 58 °C and the melting
curve was sigmoidal indicating cooperative unfolding behavior.
However, for Ala19Val SAM, there was loss of cooperativity and
absence of sharp melting point (Supplementary Fig. 12B).
Arg823Trp mutation in SAM domain of ANKS6 has been pre-
viously reported to cause structure destabilization and responsible
for polycystic kidney disease29. Interestingly, both Arg823Trp
(Arg64) mutation in ANKS6 and Ala456Val (Ala19) mutation in
DLC1 are located in proximity in DLC1-SAM domain structure
indicating a possible link of similar destabilization effect
(Supplementary Fig. 12C, D).
Fig. 1 High-throughput sequencing reveals recessive mutations ofMAGI2, TNS2, DLC1, CDK20, ITSN1, or ITSN2 as causing NS in humans. a Renal histology of
individual A5146-21 with focal segmental glomerulosclerosis (FSGS) and MAGI2 mutation (scale bar= 50 μm). b Exon structure of human MAGI2 cDNA
and mutations. Below is the protein domain structure of MAGI2, showing GuK, WW1, WW2, and six different PDZ domains. Two different homozygous
truncating mutations of MAGI2 were detected in two families with NS and neurological impairment. c Homozygosity mapping identiﬁes ten recessive
candidate loci (red circles) in family A1358 with NS, and WES identiﬁes a homozygous mutation of TNS2 (p.Arg292Gln). Non-parametric lod scores (NPL)
were calculated and plotted across the human genome. The TNS2 locus (arrowhead) is positioned within one of the maximum NPL peaks on chromosome
12q. d Exon and protein domain structure of human TNS2. Six different TNS2 mutations were detected in ﬁve families with NS. Family numbers and amino
acid changes are given (Supplementary Table 1). Arrow heads denote altered nucleotides. Lines and arrows indicate positions of mutations in relation to
exons and protein domains. Family numbers with compound heterozygous mutations (het) are highlighted in gray. e Renal histology of individual A4967-21
with FSGS and DLC1 mutations. TEM reveals podocyte foot process effacement (arrow heads, magniﬁcation 8000x). f Exon and protein domain structure of
human DLC1. The SAM, RhoGAP, and START domains are depicted by colored bars, in relation to encoding exon position. Six different DLC1 mutations were
detected in four families with NS. Positions of amino acid changes (Supplementary Table 1) are marked with arrowheads. g Renal histology of individual
A5013-21 with membranoproliferative glomerulonephritis (MPGN) and mutation in CDK20. TEM reveals podocyte foot process effacement and thickening of
glomerular basement membrane (arrow heads, magniﬁcation 7000x). h Homozygosity mapping identiﬁes twelve recessive candidate loci (red circles) in
family A5013 with NS, and WES identiﬁes a homozygous mutation of CDK20 (p.Phe204Leu), positioned within one of the maximum NPL peaks on
chromosome 9q. i Exon and protein domain structure of human CDK20. The serine threonine kinase (S_TKc) domain is depicted by a colored bar, in relation
to encoding exon position. One homozygous mutation in CDK20 was detected in family A5013 with NS. j Homozygosity mapping in family A3706 with NS
identiﬁes 17 recessive candidate loci (red circles), andWES identiﬁes a homozygous mutation of ITSN1 (p.Pro180Ser), positioned within one of the maximum
NPL peaks on chromosome 21q. k Exon and protein domain structure of human ITSN1. Five different ITSN1mutations were detected in three families with NS.
l Renal histology of Patient-1 with mutations in ITSN2 revealed minimal change disease (scale bar= 50 μm). EM showed foot process effacement (scale bar
= 2 μm). m Exon and protein domain structure of human ITSN2. Three different ITSN2 mutations were detected in two families with NS
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Knockdown of MAGI2 or CDK20 or DLC1 causes a decrease in
cell migration rate. To elucidate the role of the genes of this
RLSG regulatory module in the pathogenesis of pTSNS, we next
studied cell migration rate, which is typically altered upon loss
of function of NS-causing genes. We show that knockdown of
MAGI2 or CDK20 in cultured human podocytes results in a
reduced migratory phenotype (Supplementary Fig. 13A, B).
Similarly, knockdown of DLC1 in both IMCD3 cells and human
podocytes also show a reduction in cell migration (Fig. 2f,
Supplementary Fig. 14). This effect is found to be reversed
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when WT human DLC1 is transfected to IMCD3 cells (Fig. 2f).
In contrast, four out of six DLC1 mutants (Trp10*, Ala456Val,
Ala1352Val, and Lys1358Thr), detected in pTSNS, failed to
fully rescue this decreased migratory phenotype. The knock-
down of TNS2 did not show any effect on podocyte migration
(Supplementary Fig. 15).
RhoA regulation by this NS pathogenic module. Because defects
in the regulation of Rho-like small GTPases have been implicated
in the pathogenesis of monogenic SRNS4,5,30, we evaluated the
effect of overexpression and transient knockdown of all six
members of NS pathogenic module on the regulation of RhoA/
Rac1/Cdc42 activity (Supplementary Fig. 16, Supplementary
Table 5) and its potential impairment by the mutations detected
in patients with pTSNS. We further evaluated the effect of stable
knockdown of TNS2 and DLC1 in human podocytes, on the
regulation of RhoA/Rac1/Cdc42 activity. Our results were con-
sistent with the ﬁndings observed with the transient knockdown
for these two genes (Supplementary Fig. 17).
No effect of overexpression or knockdown of TNS2, CDK20,
ITSN1, or ITSN2 was found on the regulation of active (GTP-
bound) Rac1, with the exception of an increase of active Rac1
upon knockdown of DLC1 (Supplementary Figs 16 and 17,
Supplementary Table 5). This ﬁnding most likely indicates an
effect of the known crosstalk between RhoA and
Rac1 signaling.
We found that overexpression of MAGI2 increased active
(GTP-bound) RhoA, whereas overexpression of the MAGI2
mutants detected in patients with pTSNS lacked this effect
(Fig. 3a, Supplementary Table 5). We tested the effect of TNS2 on
RhoA regulation and found that TNS2 behaved similar to MAGI2
(Fig. 3b). Because we had shown that CDK20 interacts with the
RhoGAP DLC1 (Fig. 2a, d), we tested the effect of CDK20 on
RhoA regulation and found that CDK20 behaved similar to
MAGI2 and TNS2 in that overexpression of CDK20 increased
active RhoA, whereas overexpression of the CDK20 mutant
detected in patients with pTSNS lacked this effect (Fig. 3c). We
then tested the effect on RhoA regulation of the RhoGAP DLC1,
which interacts with MAGI2, TNS2, and CDK20. We found that
DLC1 behaved opposite to MAGI2, TNS2, and CDK20 because
overexpression of DLC1 decreased active RhoA. Overexpression
of the DLC1 mutants detected in patients with pTSNS again
lacked this effect (Fig. 3d). Reciprocally, knockdown of MAGI2,
TNS2, and CDK20 decreased active RhoA, which was rescued by
overexpression of respective WT cDNAs, whereas all or most of
the mutants detected in patients with pTSNS lacked this effect
(Fig. 3e–g, Supplementary Table 5). However, knockdown of
DLC1 was found to increase active RhoA (Fig. 3h). We thereby
clearly showed that the mutations detected in individuals with
pTSNS in the six genes of this newly discovered RhoA regulatory
module are an important part of the pathogenesis of pTSNS. We
also tested the effect of CAV1 on RhoA activation and found that
its overexpression decreases active RhoA, whereas its knockdown
increased active RhoA (Supplementary Fig. 18).
We then tested the effect of double-knockdown of TNS2 and
DLC1 on RhoA activity and found that the decrease in active
RhoA by TNS2 knockdown or increase in active RhoA by DLC1
knockdown was normalized (Fig. 3i, Supplementary Table 5). To
test if the TNS2 expression modulates the RhoA activity via
DLC1, we knockdown DLC1, followed by overexpression of WT-
TNS2 in HEK293T cells and found the increase was comparable
to knockdown of DLC1 alone (Fig. 3j). This conﬁrms that the
TNS2 is upstream of DLC1 and works via DLC1 on RhoA
regulation. Similarly, knockdown of DLC1 and CDK20 together
(Fig. 3k) also showed that both CDK20 and MAGI2 affect RhoA
regulation via DLC1, which plays a central role in this
pathogenesis. In contrast, the double-knockdown of DLC1 and
MAGI2 did not (Fig. 3l).
Defects of RhoA regulation are mitigated by steroids. Since
most of the individuals found here with mutations in MAGI2,
TNS2, DLC1, or CDK20 genes had clinically shown beneﬁts by
treatment with steroids, we next tested if steroid treatment with
dexamethasone in different concentrations will show any the
effect on the increase of RhoA activity upon DLC1 knockdown in
HEK293T cells. Wild type HEK293T cells showed no effect of
dexamethasone treatment on active RhoA, while they responded
to RhoA activators (red) and RhoA inhibitors (blue) as a positive
controls (Supplementary Fig. 19). In contrast, treatment with
dexamethasone at >75 µM abolished the effects on RhoA acti-
vation by knockdown of DLC1 (Fig. 3m). We observed similar
treatment effect of dexamethasone (>75 µM) on RhoA activation
via knockdown of CDK20 (Fig. 3n). However, no treatment effect
of dexamethasone (<100 µM) was seen on RhoA activation via
knockdown of MAGI2, TNS2, or CAV1 (Fig. 3n). We further
conﬁrmed these ﬁndings in human podocyte cells (Supplemen-
tary Fig. 20). This indicates that the beneﬁcial effect of steroids in
pTSNS and mutations in these genes is likely mediated by the
RhoA-regulating module.
Discovery of ITSN1 and ITSN2 as two NS-relevant GEFs for
Cdc42. We here discover recessive mutations in ITSN1 and
Fig. 2 Gene products ofMAGI2, TNS2, DLC1, CDK20, and CAV1 physically and functionally interact to regulate RhoA/Rac1/Cdc42 activation. a Identiﬁcation
of six novel monogenic causes of NS reveals a regulatory network of RhoA activation. The large rounded square symbolizes a podocyte. All six proteins
MAGI2, TNS2, DLC1, CDK20, ITSN1, and ITSN2, in which recessive defects were detected herein as novel causes of pTSNS, interact physically or
functionally to regulate RhoA/Rac1/Cdc42. Yellow labels highlight proteins encoded by genes, which if mutated give rise to monogenic nephrosis as shown
in this study (MAGI2, TNS2, DLC1, CDK20, ITSN1, and ITSN2) or as published (EMP2, ARHGDIA). Blue frame around yellow labels indicate that there is
also a monogenic mouse model of NS or a zebraﬁsh model known, as shown in this study for ITSN2 or as published for MAGI2, TNS2, EMP2, and RhoGDI-
α. For each of the proteins, MAGI2, TNS2, DLC1, CDK20, TLN1, or ITSN1, the protein domains are shown. Red circles denote positions of mutations that we
found in patients. Truncation mutations are represented by “x”. By identifying novel monogenic causes of NS we discovered a cluster proteins that regulate
Rho/Rac/Cdc42 activation as being central for the pathogenesis of these patients. b MAGI2 interacts with TNS2 upon co-overexpression and
coimmunoprecipitation (coIP) in HEK293T cells. Both mutant MAGI2 clones, Gly39* and Tyr746* (underlined) that reﬂect alleles of NS patients A5146-21
and B91 respectively, abrogate this interaction. cMAGI2 interacts with DLC1 upon co-overexpression and coIP in HEK293T cells. One mutant MAGI2 clone
Gly39* (underlined) reﬂecting a mutation of NS patient A5146-21 abrogates this interaction. d DLC1 interacts with CDK20 upon co-overexpression in
HEK293T cells. e DLC1 interacts with CAV1. Two mutant DLC1 c-DNA clones, reﬂecting Trp10* and Lys1358Thr alleles of NS patients A548-21 and A4967-
21 respectively, lack this interaction. f In IMCD3 cells, migration rate is induced in the presence of serum as compared to scrambled control. Knockdown of
Dlc1 in IMCD3 cells using mouse Dlc1 siRNA #1 impairs cell migration rate (red vs. black curve with serum). The decrease in migration is rescued by
transfection with full-length human DLC1 cDNA (green curve). Transfection with four out ot six mutants (Trp10*, Ala456Val, Ala1352Val, and Lys1358Thr)
failed to rescue this migratory phenotype
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ITSN2 as causing NS. Both proteins are members of the guanine
exchange factor (GEF) family of proteins that activate Cdc4231
(Fig. 2a). To test whether loss of function of ITSN1 and ITSN2
GEF activity causes a nephrosis phenotype in humans, we
examined the effect of mutations identiﬁed in patients with
pTSNS on the active states of Cdc42. We show that over-
expression of WT-ITSN1 results in a signiﬁcant increase in active
Cdc42 in HEK293T cells (Fig. 4a) or human podocytes (Sup-
plementary Fig. 21). All of the ITSN1mutants detected in patients
with pTSNS lacked this effect, demonstrating its relevance for the
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pathogenesis of NS. Similar results were obtained for ITSN2
where all the mutations detected in pTSNS patients lacked the
effect of Cdc42 activation (Fig. 4b). Filopodia, thin actin-rich
plasma-membrane protrusions, play an important role in cell
migration and wound healing32 and Cdc42 is a key protein
involved in ﬁlopodia formation33. Thus, we examined the effect of
ITSN1 and ITSN2 mutations on ﬁlopodia induction in cultured
human podocytes. Human podocyte cells were co-transfected
with Myc-Cdc42 and FLAG tagged WT-ITSN1, ﬁve mutants
discovered in pTSNS patients (Pro180Ser, Glu302Gly,
Asp852Asn, Lys1476Glu, and Lys1517Arg) or ﬂag-mock and
images were captured (Supplementary Fig. 22). WT-ITSN1
transfected cells induced dense ﬁlopodia all around the cell sur-
faces (Supplementary Fig. 22). Overexpression of ITSN1 mutants
resulted in a signiﬁcant decrease in the ratio of cells with ﬁlopodia
compared to WT-ITSN1 (Fig. 4c). Similar loss of ﬁlopodia
induction was observed for overexpression of ITSN2 wild type vs.
three mutants discovered in pTSNS patients (Ser339Cys,
Glu438Gly and Ile1214Serfs*2) (Fig. 4d, Supplementary Fig. 23).
We thus demonstrated that the ITSN1 and ITSN2 mutations
detected from the pTSNS families cause loss of function in
Cdc42-GEF activity and also inhibit ﬁlopodia induction in cul-
tured human podocytes cells. The other genes were not tested
because their overexpression or knockdown altered RhoA activ-
ity, which induces focal adhesions, rather than Cdc42, which
induces ﬁlopodia.
Generation of Itsn2 deﬁcient mice. To evaluate the pathogenic
roles of ITSN2 mutations in the pTSNS disease phenotype, we
generated Itsn-L KO mice. In the KO mice, a region including
exon 31 of Itsn2 (NC_000078) was replaced with the targeting
vector throughout the entire body (Supplementary Fig. 24A). This
region encodes a part of the DH domain, affecting Cdc42-GEF
activity. The expression level of Itsn2-S and Itsn2-L mRNA in
various organs were determined by reverse transcription PCR
(RT-PCR; Supplementary Fig. 24B). Itsn2-S and Itsn2-L mRNA
were expressed ubiquitously in wild type mice. In the homo-
zygous KO (Itsn2L−/L−) mice, Itsn2-L mRNA was not detected
(Supplementary Fig. 24B). Itsn2 L−/L− mice were normal in
appearance, growth, development, and fertility. There was no
difference between Itsn2 L−/L− and wild-type mice in the histo-
logic ﬁndings of the kidneys (Fig. 4e) and in the level of urinary
protein (Fig. 4f at 0 h) during the course of natural history. These
results suggested that Itsn2-L is not necessary for kidney devel-
opment in mice. Patients with NS often relapse after an upper
respiratory tract infection34. We hypothesized that some inter-
ventions that mimic infectious events may trigger the onset of a
nephrosis phenotype in Itsn2L−/L− mice. We used the LPS model
of transient nephrotic syndrome, in which foot process efface-
ment and massive proteinuria of wild-type mice develop within
12–24 h and return to baseline levels within 72 h35. The time
course of albuminuria was measured in wild type, Itsn2 +/L− and
Itsn2 L−/L− mice at various time points before and after the
injection of LPS (Fig. 4f). There was no difference in urine
albumin between wild-type and Itsn2L−/L− mice before the
injection of LPS. Urine albumin was increased in Itsn2L−/L−
mice from 12 to 48 h after LPS injection, with statistically sig-
niﬁcant differences at 12 and 36 h compared with WT mice and
Itsn2 +/L−mice. At 36 h of observation, albuminuria continued to
be elevated in Itsn2 L−/L− mice, while it started to decline in WT
and Itsn2 +/L− mice. In all groups, urine albumin returned to
baseline at 60 h. To conﬁrm whether the urinary phenotype
reﬂected pathologic ﬁndings, we examined the electron micro-
scopy of mice kidneys. LPS injection induced foot process (FP)
effacement in both WT and Itsn2L−/L− mice within 24 h. At 48 h
after LPS injection, FP were almost recovered in WT mice, while
diffuse FP effacement was observed in Itsn2L−/L− mice (Fig. 4g).
We thereby demonstrated that ITSN2-L knockout caused delayed
recovery from podocyte injury. This ﬁnding adds yet another
example of a pathogenic role of small Rho-like GTPases (here
Cdc42), in which there is incomplete penetrance of the disease
phenotype, analogous to the partially treatment sensitive phe-
notype (pTSNS) seen in mutations in the RhoA regulatory
module members—MAGI2, TNS2, DLC1, and CDK20 (Fig. 2a).
Discussion
We here discover recessive mutations of MAGI2, TNS2, DLC1,
CDK20, ITSN1, and ITSN2 genes as novel causes of NS. Whereas
over 50 monogenic genes have been published to cause steroid
resistant nephrotic syndrome (SRNS), if mutated, there is vir-
tually no monogenic cause known for steroid sensitive nephrotic
(SSNS) syndrome, the latter including steroid dependent (SDNS)
and frequently relapsing nephrotic syndrome (FRNS). Thus,
SRNS and SSNS have always appeared as molecularly and func-
tionally completely separate entities. Therefore our ﬁnding that
nine of the 12 patients with mutations in one of the six genes of
Fig. 3 The novel RhoA regulatory network of MAGI2, TNS2, DLC1, CDK20, and CAV1 is a central part of the pTSNS pathogenesis. a Overexpression of
GFP-tagged MAGI2 wild type (WT) but not the two MAGI2 mutants from pTSNS patients resulted in a signiﬁcant increase in active RhoA. Active RhoA
was measured by G-LISA assay in HEK293T cells. b Myc-tagged TNS2-WT increased active RhoA levels upon overexpression in HEK293T cells as
compared to Mock. However, all six TNS2 mutant clones from pTSNS patients failed to increase active RhoA. c GFP-tagged CDK20-WT showed a
signiﬁcant increase in active RhoA level upon overexpression in HEK293T cells, while the mutant clone Phe240Leu, from a pTSNS patient, failed to do so. d
Myc-tagged DLC1-WT showed a signiﬁcant decrease in active RhoA level upon overexpression in HEK293T cells as compared to Mock. However, none of
the six DLC1mutant clones from pTSNS patients showed this effect. e siRNA mediated knockdown ofMAGI2 decreased active RhoA. The overexpression of
Magi2-WT rescued this effect while both the mutants from pTSNS patients did not. f siRNA mediated knockdown of TNS2 decreased active RhoA. The
overexpression of TNS2-WT rescued this effect, while four out of six TNS2 mutant clones from pTSNS patients did not. g siRNA mediated knockdown of
CDK20 decreased active RhoA. This effect was rescued by the overexpression of CDK20-WT, but not by the overexpression of mutant clone Phe240Leu. h
siRNA mediated knockdown of DLC1 showed a signiﬁcant increase in active RhoA. i siRNA mediated knockdown of TNS2 or DLC1 in HEK293T cells
decreased or increased active RhoA levels, respectively, as compared to scrambled control. The parallel knockdown of both TNS2 and DLC1 rescued this
effect on active RhoA. j siRNA mediated knockdown of DLC1 increased active RhoA and this effect was unaltered upon overexpression of TNS2 in DLC1
knockdown cells, suggesting that TNS2 modulates RhoA activity indirectly via DLC1. k siRNA mediated knockdown of DLC1 or CDK20 in HEK293T cells
increased and decreased active RhoA levels, respectively, as compared to scrambled control. The combined knockdown of both DLC1 and CDK20 rescued
this effect on active RhoA. l siRNA mediated knockdown of DLC1 or MAGI2 in HEK293T cells increased and decreased active RhoA levels, respectively, as
compared to scrambled control. The combined knockdown of both DLC1 and MAGI2 failed to rescue this effect on active RhoA. m Treatment with
dexamethasone (75 and 100 µM) inhibited in a dose-dependent manner the increase of active RhoA elicited by DLC1 knockdown. n The change in active
RhoA upon knockdown of CDK20, but not MAGI2, TNS2, or CAV1 was found reversible by treatment of HEK293T cells with 100 µM dexamethasone. Error
bars are deﬁned as the standard error of at least three independent experiments. One-way ANOVA with Dunnet’s post hoc test was performed vs. control.
Data are presented as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. ns, non signiﬁcant
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the “Rho-like small GTPase regulatory cluster” had a partially
treatment responsive form of nephrotic syndrome is quite strik-
ing and has not been described in a similar way before. This
ﬁnding conﬁrms the unique role of the pathway discovered that
maybe amenable to therapy.
RhoA/Rac1/Cdc42 regulation has been implicated in SRNS
before36 and few genes that code the regulators of Rho GTPases
were found to be associated with human glomerular disease. We
showed that ARHGDIA, which encodes a GDI for Cdc42 and
Rac1, causes autosomal recessive SRNS4. In addition, patients
with NS and mutations in KANK2, which encodes kidney ankyrin
repeat-containing protein 2, exhibited increased active RhoA in
podocytes5. Furthermore, we demonstrated that mutations in
FAT1 cause familial focal segmental sclerosis (FSGS) via defective
Rho GTPases30. Podocyte-speciﬁc loss of Cdc42 in mice has been
described to lead to foot process effacement and congenital
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proteinuria37. It has been suggested that there is strong crosstalk
between the three Rho-like small GTPases RhoA, Rac1, and
Cdc4238. Therefore, we here evaluated activation of all three Rho-
like small GTPases by G-LISA for each of the six novel mono-
genic causes of pTSNS. In contrast to previous ﬁndings showing a
role of Rac1 in SRNS of humans, mice and zebraﬁsh4, and a role
of Cdc42 in NS in mouse models37, we here discovered that for
four different novel genes (MAGI2, TNS2, CDK20, and DLC1),
which if mutated cause pTSNS, modulation of activated RhoA
rather than Rac1 or Cdc42 is central to the pathogenesis (Sup-
plementary Table 6). This may indicate that in pTSNS caused by
mutations in these four genes impairment of the RhoA-driven
function of focal adhesions is more relevant for the pathogenesis
than impairment of Rac1-driven lamellipodia formation.
Mechanisms of steroid action in NS have been a conundrum
for the six decades of their use. Interestingly, we found that the
effects of KD of DLC1 or CDK20 on RhoA activation in human
podocytes and HEK293T cells were abolished by steroid treat-
ment with dexamethasone. We here generate evidence of steroid
action on podocyte function indicating that this newly delineated
RLSG regulatory module mediates the beneﬁcial effect of steroids
in patients with pTSNS and mutations in these genes. We cannot
evidently answer why steroids help cure NS in some patients, and
it has been only known that steroids may inﬂuence the tran-
scription of a large number of genes by virtue of their interaction
with intracellular receptors. However, our data suggests that
steroids might target a speciﬁc protein or modulator of protein,
which is most likely a part of the complex described in this
manuscript, rather than the transcriptional target through the
receptors. Further studies of this protein interaction module may
reveal the speciﬁc target(s) of steroid action in podocytes.
Tns2-deﬁcient mice have been previously described to develop
mild glomerular injury on a DBA/2 background, but not on a
C57BL/6J or a 129/SvJ background, suggesting that glomerular
injury by the deletion of Tns2 was modiﬁed by the genetic
background39. In mice, LPS stimulates toll-like receptor-4 (TLR-
4) and upregulates CD80 expression on podocytes, resulting in
foot process effacement and transient proteinuria35. Here, we
generated the Itsn2-L knockout mice with partially penetrant
proteinuria following LPS injection. This mouse model exhibits
an NS phenotype that is at an interphase between plain steroid
resistance and steroid sensitivity. We observed that the indivi-
duals with ITSN2 mutations had frequently relapsing NS while
the Itsn2-L knockout mouse showed inducible and transient
proteinuria. In humans, the severity of SSNS varies, where some
patients show complete remission with steroid therapy while
some have frequently relapsing NS. The study by Wharram et al.
published in J. Am. Soc. Nephrol. in 200540 described that the
different levels of podocyte depletion assess the level of glomer-
ulosclerosis in the transgenic rat model. This means that indu-
cible, partially sensitive, and frequently relapsing NS are all on a
spectrum with steroid-resistant NS. Furthermore, SSNS maybe a
multifactorial disease and not a simple Mendelian disorder. It
may also be inﬂuenced by multiple modifying genes and envir-
onmental factors such as infections and nature of host immune
responses, besides mutation in a particular gene. Therefore, the
nephrotic phenotype of Itsn2-L knockout mice may vary greatly
depending on genetic background of mouse strain and environ-
mental factors, conﬁguring a phenotypic spectrum of the Itsn2-
related NS. Therefore, it is not surprising that Itsn2-L knockout
mouse did not mimic the symptoms of the patients with ITSN2
mutations.
In summary, we detected recessive mutations in cohort of
individuals with partially treatment sensitive NS, which places
this pathogenesis at the interphase between SSNS and SRNS.
Deﬁnition of this pathogenic pathway opens inroads into deﬁning
therapeutic targets for SRNS, for which currently no efﬁcient
treatment exists.
Methods
Study participants. We obtained blood samples and pedigrees following informed
consent from individuals with NS. Approval for human subjects’ research was
obtained from Institutional Review Boards of the University of Michigan, the
Boston Children’s Hospital and other local IRBs. The diagnosis of NS was based on
published clinical criteria. This study was also approved by the Ethical Committee
of Tohoku University Graduate School of Medicine. Written informed consent was
obtained from all members of the Japanese families and the individuals with SSNS
for the use of their clinical data and blood samples.
Linkage analysis. For genome-wide homozygosity mapping the GeneChip®
Human Mapping 250 k StyI Array from Affymetrix was used. Non-parametric
LOD scores were calculated using a modiﬁed version of the program GENE-
HUNTER 2.141,42 through stepwise use of a sliding window with sets of 110 SNPs
and the program ALLEGRO43 in order to identify regions of homozygosity as
described10,44 using a disease allele frequency of 0.0001 and Caucasian marker
allele frequencies.
Whole exome sequencing. Whole exome sequencing (WES) and variant burden
analysis was performed as described45. In brief, genomic DNA was isolated from
blood lymphocytes and subjected to exome capture using Agilent SureSelect™
human exome capture arrays (Life technologiesTM) followed by next generation
sequencing on the IlluminaTM sequencing platform. For family from Japan, exon
capture was performed with SureSelectXT Human All Exon V4 (51Mb) Kits
(Agilent Technologies). Exome libraries were sequenced on a HiSeq2000 (Illumina)
according to the manufacturer’s instructions. Paired reads were aligned to the hg19
human reference using Novoalign V2.08.05 (http://novocraft.com), and single
nucleotide variants (SNVs) and insertions and/or deletions (indels) were called
using the Genome Analysis Toolkit (GATK) v1.6-1346.
Fig. 4 ITSN1 and ITSN2 are GEFs for Cdc42, regulating NS-related podocyte function, and Itsn2−/− mice develop incompletely penetrant NS upon LPS
injection. a Myc-tagged ITSN1-WT increased active Cdc42 levels upon overexpression in HEK293T cells as compared to mock, whereas three out of ﬁve
ITSN1 mutants from pTSNS patients failed to show any signiﬁcant increase in active Cdc42 upon overexpression. b Active Cdc42 level was measured in
COS7 cells. Myc-tagged ITSN2-WT overexpression increased active Cdc42 levels as compared to Mock. However, all three ITSN2 mutants from pTSNS
patients failed to show any signiﬁcant increase in active Cdc42 upon overexpression. Error bars are deﬁned as the standard error of at least four
independent experiments. One-way ANOVA with Dunnet’s post hoc test vs. wild-type (WT) ITSN2 expressing control. c Filopodia induction in cultured
human podocytes was quantiﬁed by counting the transfected cells with ﬁlopodia and showed as a percentage of cells. For each construct, 50 transfected
cells from three independent experiments were analyzed. One-way ANOVA with Dunnet’s post hoc test vs. WT ITSN1 expressing control. Data are
presented as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. d Filopodia induction in cultured human podocytes was quantiﬁed by
counting the transfected cells with ﬁlopodia and showed as a percentage of cells. For each construct, 50 transfected cells from three independent
experiments were analyzed. One-way ANOVA with Dunnet’s post hoc test vs. WT ITSN2 expressing control. Data are presented as the mean ± SEM. * P <
0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. e Kidneys of WT and Itsn2 L−/L− mice were stained with periodic acid Schiff. The glomeruli of Itsn2 L−/L−
mice showed normal ﬁndings, similar to WT. f Urine albumin of Itsn2 L−/L−, Itsn2 +/L−, and WT mice was measured before and after LPS injection.
Albuminuria level was increased in Itsn2 L−/L− mice from 12 to 48 h after LPS injection compared with WT and Itsn2 +/L− mice. Two-tailed Student’s t-
tests. Data are presented as the mean ± SEM. *P < 0.05. g Representative electron microscopy images. LPS injection-induced foot process (FP) effacement
in both WT and Itsn2 L−/L−mice within 24 h. At 48 h after LPS injection, FP effacement was still observed in Itsn2 L−/L−mice, although WT mice recovered
from FP effacement
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Targeted sequencing. DNA was obtained from 153 individuals with SSNS by the
group from Japan. The 153 patients screened for ITSN2 mutations were screened
by panel sequencing rather than by whole exome sequencing. We designed a
custom panel of 21 genes (total target bases: 183.44 kbp, Supplementary Table 7)
using the SureDesign Tool (Agilent Technologies). Target capture was performed
with the HaloPlex target enrichment system (Agilent Technologies). Libraries were
sequenced on a MiSeq or HiSeq2000 (Illumina). Mapping and variant call were
performed using SureCall v2.1.0.21. Variants in ITSN2 were manually veriﬁed
using an Integrative Genomics Viewer (IGV), and nonsynonymous mutations were
retained and ﬁltered for a MAF < 0.01 in the 1000 Genomes database and HGVD.
Mutation calling. Sequence reads were mapped against the human reference
genome (NCBI build 37/hg19) using CLC Genomics Workbench (version 6.5.1)
software (CLC bio). Variants with minor allele frequencies <1% in the dbSNP
(Version 137) database were selected and annotated for impact on the encoded
protein and for conservation of the reference base and amino acid among orthologs
across phylogeny. Mutation calling was performed by geneticists/cell biologists,
who had knowledge of the clinical phenotypes and pedigree structure, as well as
experience with homozygosity mapping and exome evaluation.
High-throughput mutation analysis by array-based multiplex PCR and NGS.
We used PCR-based 48.48 Access Array microﬂuidic technology (FluidigmTM)
with consecutive next generation sequencing. We applied a 12-fold primer mul-
tiplexing approach allowing PCR-based ampliﬁcation for 48 DNA samples
simultaneously in 576 amplicons12,13. A total of 2000 individuals with NS were
analyzed, among them subset of 800 individuals with SSNS. After ampliﬁcation of
all targeted coding and splice site regions, sample-derived products were indexed
with 384 different 10 bp-barcodes in a subsequent PCR. Finally, 2 × 250 bp paired-
end sequencing was performed on an IlluminaTM MiSeq instrument. Bioinformatic
analysis was conducted using CLC-Genomics-WorkbenchTM software. Potential
mutations were conﬁrmed by Sanger sequencing and evaluated for segregation.
cDNA cloning. Rat Magi2 (S-SCAM) full-length cDNA was gifted by Dr. Min Loo,
Yonsei University College of Medicine, Korea. Human TNS2 isoform 2 full-length
cDNA was subcloned by PCR from human full-length cDNA (cDNA clone MGC:
165058, IMAGE: 40148847). Mouse TNS2 was subcloned from mouse TNS2 full-
length ORF cDNA (Cat No: MR211954, Origene). Human DLC1 subcloned from
human fetal brain cDNA library (Clontech). Human CDK20 full-length was sub-
cloned from human full-length cDNA (cDNA clone MGC: 3757, IMAGE:
3605918). Mouse Cdk20 was subcloned from mouse full-length Cdk20 (cDNA
clone, MGC: 38901, IMAGE: 5362198). Human ITSN1 full-length was subcloned
from human full-length cDNA (cDNA clone MGC: 134949 IMAGE: 40073781).
Expression vectors were produced using LR clonase (Invitrogen®) following the
manufacturer’s instruction. The coding sequences of human ITSN2-L was pur-
chased from Origene, and the ITSN2-L with the N-terminal FLAG tag (FLAG-
ITSN2-L) or FLAG (mock) was subcloned into pCAGEN using the In-Fusion® HD
Cloning Kit (TaKaRa, Clontech). The following expression vectors were used in
this publication: pRK5-N-Myc, pCDNA6.2-N-GFP, pCMV6-AN-DDK (Origene)
or pCAGEN. pCAGEN was a gift from Connie Cepko (Addgene plasmid # 11160)
47. Clones reﬂecting the mutations identiﬁed in individuals with NS were intro-
duced in the cDNA constructed by using the Quick change II XL site-directed
mutagenesis kit, Agilent Technologies or by the PrimeSTAR® Mutagenesis Basal
Kit (TaKaRa). Final sequences were conﬁrmed by sequencing. pRK5-Myc-Cdc42-
WT was a gift from Gary Bokoch (Addgene plasmid # 12972).
Cell lines. Experiments shown in this publication were performed in
HEK293T cells, and immortalized human podocytes. HEK293T cells were pur-
chased from the ATCC biological resource center. Human immortalized podocytes
were a kind gift from Moin Saleem, University of Bristol, Bristol, UK, and were
cultured as previously described48. Cell lines were tested for mycoplasma con-
tamination on a quarterly basis.
Coimmunoprecipitation. Coimmunoprecipitation experiments were performed as
described previously49. Brieﬂy, cell lysates were pre-cleared with protein G or A
beads. Then, cell lysates were mixed with the appropriate antibodies and incubated
overnight at 4 °C in lysis buffer containing the complete protease inhibitor mixture.
Immune complexes were collected by binding to mixed protein G or A beads and
washed four times with lysis buffer prior to immunoblotting. Coimmunoprecipi-
tation of GFP fusion proteins was performed using Chromotek-GFP-Trap®
Agarose Beads, allele bioscience.
Knockdown in HEK293T cells and human podocytes. Knockdown efﬁciencies
for respective siRNAs in HEK293T cells for TNS2, DLC1, CDK20, and ITSN1 are
shown in Supplementary Fig. 25 and for CAV1 in Supplementary Fig. 26. Efﬁciency
of transient knockdown of MAGI2, TNS2, DLC1, CDK20, and ITSN1 in undif-
ferentiated human podocytes was conﬁrmed by measuring mRNA levels by real-
time PCR using TaqMan probes (Supplementary Fig. 27). All target sequences are
listed in Supplementary Table 8. Knockdown experiments were performed 48 h
after transfection. shRNA targeting human TNS2 and DLC1 were subcloned into
pSirenRetroQ for retroviral transduction using HEK293T cells. Forty eight hour
after transduction, puromycin was added to the medium at a ﬁnal concentration of
4 μg/ml for selection of transduced cells. See Supplementary Table 8 for target
sequences and Supplementary Fig. 28 for knockdown efﬁciency.
Cell migration assay. Brieﬂy, the migration assays were performed using Incu-
Cyte™ video-microscopy system (Essen Biosciences) according to the manu-
facturer’s instructions. IMCD3 cells or human podocytes were transfected with
siRNAs for DLC1, MAGI2, CDK20, or TNS2. For rescue experiments (Fig. 2f),
knockdown of Dlc1 in IMCD3 cells was followed by transfection with mock-myc
or human DLC1 WT or mutants. Results were plotted as percentage of wound
conﬂuence (relative podocyte migration) vs. time. Each experiment was performed
at least in triplicates, and repeated two times independently. Results are presented
as mean with standard deviation.
G-LISA Rho, Rac, and Cdc42 activation assays. Cells were transfected in six-well
plates with WT constructs or mock using Lipofectamine-2000 for overexpression
experiments, or with siRNA against the target or scrambled control using
Lipofectamine-RNAiMAX for knockdown experiments. Transfected cells were
incubated in DMEM (HEK293T) or RPMI (human podocytes) with 10% fetal
bovine serum for 8 h and then in serum-free medium for 24 h. Rho, Rac, or Cdc42
activity was determined using a colorimetric G-LISA Rho or Rac or Cdc42 Acti-
vation Assay Biochem kit (Cytoskeleton), according to the manufacturer’s
instructions.
Measurement of ﬁlopodia induction in human podocytes. Human podocyte
cells on glass coverslips were transfected with CDC42 constructs and ITSN1 or
ITSN2 constructs or pCAGEN-FLAG-mock using Lipofectamine 2000® in six-well
plates and were incubated in RPMI with 10% fetal bovine serum for 8 h and then in
serum-free medium for 24 h. Cells were ﬁxed in 4% paraformaldehyde (PFA) for
10 min and containing 0.25% Triton X-100. Cells were stained for 60 min at room
temperature (RT) with mouse monoclonal anti-FLAG antibodies (1:500, Sigma-
Aldrich, F3165) and rabbit polyclonal anti-Myc antibodies (1:500, santa cruz, sc-
789), washed with phosphate-buffered saline (PBS) and incubated for 1 h at RT
with Alexa Fluor 647 anti-mouse secondary antibody (1:500, life technologies,
A31571), Alexa Fluor 594 anti-rabbit secondary antibody (1:500, life technologies,
A21207) and Alexa Fluor 488 Phalloidin (1:40, Invitrogen, A12379). Coverslips
were then mounted on slides with ProLong Gold antifade reagent with DAPI
(Invitrogen). Confocal imaging was performed using Leica SP5X system with an
upright DM6000 microscope and images were processed with the Leica AF soft-
ware suite. Filopodia were deﬁned as thin, ﬁnger-like protrusive structures32. The
ratio of cells with ﬁlopodia was calculated.
Circular dichroism (CD). The WT-DLC1 SAM domain (amino acid number
17–76) was cloned in pETM vector as described50. A19V point mutation was
incorporated in WT construct by site directed mutagenesis. The mutated DNA was
transformed into Escherichia coli XL1-blue cells and plated on antibiotic containing
agar plate. The correct in frame mutations were conﬁrmed by sequencing of
selected clones. The pET-M plasmids were transformed into E. coli BL21 (DE3)
cells and the cells were grown in LB broth at 37 °C. Protein expression was induced
by adding 1 mM IPTG. The cells were harvested and lysed by sonication in lysis
buffer containing 20 mM Tris-HCl (pH 8), 200 mM NaCl, 5 mM DTT, 1% Triton
X-100, 5% Glycerol, and protease inhibitor (Roche). The cleared lysates was
transferred to previously washed Ni-NTA beads for overnight binding. Protein
with 6x His tag was eluted from beads in two step elution in buffer 20 mM Tris-
HCl (pH 8), 150 mM NaCl, 5% Glycerol, 5 mM DTT, and 200–300 µM Immida-
zole. The eluted protein was loaded on pre-equilibrated Superdex 75 column for
further puriﬁcation by size exclusion chromatography. CD spectrum was collected
for WT and mutant protein samples on a Jasco J-810 CD spectropolarimeter with
protein concentration ~30 µM in 10 mM Tris (pH 8) and 75 mM NaCl. Spectra
were recorded in a cuvette of path length 0.1 mm. The melting curves were
obtained by recording the CD signals at 222 nm across the temperature range from
20 to 90 °C. The reading was taken at every 2 °C increase of temperature.
Antibodies. For immunoﬂuorescence experiments the following primary anti-
bodies were used: rabbit anti-TNS2 (Sigma, HPA034659, 1:100); mouse anti-DLC1
(BD Biosciences, clone 3, 1:200); rabbit anti-ITSN1 (Abcam, ab118262, 1;100); and
rabbit anti-ITSN2 (Abcam, ab176592, 1:100). Donkey anti-goat Alexa 488 (1:500)
and Alexa-594 (1:500) conjugated secondary antibodies, and DAPI (4ʹ,6-Diami-
dino-2-Phenylindole, Dihydrochloride, 1:10,000) were obtained from Invitrogen
(Supplementary Fig. 29). For immunoblotting the following primary antibodies
were used: CDK20 rabbit polyclonal (Novus, NBP1-91214, 1;1000); ITSN1, rabbit
polyclonal (Abcam, ab118262, 1:1000). Antibodies against TNS2 or DLC1 used
here have been described51,52 (Supplementary Fig. 25). HRP labeled secondary
antibodies were purchased from Santa Cruz.
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Immunoﬂuorescence and confocal microscopy in cell lines. For immuno-
staining human immortalized podocytes were seeded on coverglasses, and grown at
permissive temperature. For overexpression studies human podocytes were tran-
siently transfected using lipofectamine 2000® following the manufacturer’s
instructions. Experiments were performed 24–48 h after transfection. Cells were
ﬁxed and permeabilized for 10 min using 4% paraformaldehyde and 0.25%Triton-
X100. After blocking, cells were incubated over-night at 4 °C. The cells were
incubated in secondary antibodies for 90 min at room-temperature, followed by 5
min staining with 1 × DAPI/PBS. Confocal imaging was performed using Leica
SP5X system with an upright DM6000 microscope and images were processed with
the Leica AF software suite.
Itsn2-L knockout mice. All animal experiment protocols were approved by The
Institutional Animal Care and Use Committee of Tohoku University. Mice were
housed in a temperature- and humidity-controlled room, with a 12-h light/dark
cycle and were allowed access to food and water ad libitum. Generation of the
Itsn2-L knockout mice were entrusted to Unitech (Chiba, Japan). The targeting
vector replaced a region that included exon 31 of Itsn2 (NC_000078; Supple-
mentary Fig. 24) so that the ITSN2 long isoform, which has Cdc42-GEF activity,
was absent throughout the entire body of the mice. The knockout mice were
produced on a background of C57BL/6. Genotyping was performed by real-time
PCR using a HybProbe assay as previously described53. The primers and probes
were designed as follows: 5ʹ-CTTCCTCACTGAAGCAGAC-3ʹ (forward primer for
wild-type), 5ʹ-TGCTCCAGACTGCCTTG-3ʹ (forward primer for knockout), 5ʹ-
TGCTCCTGCTTGGAGAT-3ʹ (reverse primer), 5ʹ-CGGGGGCTGCTCAGCAA-
FITC-3ʹ (upstream probe for wild-type), 5ʹ-TCAAGCTTATCGATGATATCA-
FITC-3ʹ (upstream probe for knockout), 5ʹ-LCRed640-ACAACTTC-
CAACTCTGTTCTGTC-P-3ʹ (downstream probe). Template DNA was extracted
from tails. To conﬁrm the loss of Itsn2-L mRNA transcripts, RT-PCR was per-
formed. Total RNA was isolated from the kidney, liver, heart, and brain of Itsn2-
knockout mice and wild type mice using an RNeasy Mini Kit (Qiagen). Using a
PrimeScript II High Fidelity RT-PCR Kit (TaKaRa Bio), 500 ng of RNA was reverse
transcribed. Total RNA was ampliﬁed using the following primer set: 5ʹ-
CACGCTGTATGTCAAGTGATTGC-3ʹ (forward primer) 5ʹ-
CATTGGGTCACTGTTGACTTGG-3ʹ (reverse primer for Itsn2 short) 5’-
CTTCAGTGAGGAAGCCTGACTCAG-3’ (reverse primer for Itsn2 long).
LPS-induced proteinuria and electron microscopy. Transient proteinuria was
induced by LPS injection as described54. We injected 4- to 6-week-old female
C57BL/6 (n=18), Itsn2+/L− (n=10), and Itsn2L−/L− (n=10) mice with LPS (200 µg
intraperitoneally (i.p.); SIGMA Aldrich). Urine samples were obtained from indi-
vidual mice at various time points before (0 h) and after (12, 24, 36, 48, 60, and 72
h) the injection of LPS. Urinary albumin and creatinine were measured using an
Albuwell M kit and the creatinine companion kit (Exocell) according to the
manufacturer’s protocol. Albuminuria was calculated as micrograms of albumin
per milligram creatinine. Kidneys were dissected from WT and Itsn2-L−/− mice 24
and 48 h after LPS injection. Specimens for EM were ﬁxed with 2% PFA and 2.5%
glutaraldehyde, washed with 0.1 M cacodylate buffer, and incubated with 1% OsO4
for 90 min. The sections were counterstained with 1% uranyl acetate for 50 min,
dehydrated in a graded series of ethanol (50, 60, 70, 80, 90, and 95%), and ﬁnally
embedded in Epon 812. Ultrathin sections (80 nm) were cut with a Leica EM UC7
(Leica) and mounted in copper grids. Images were obtained using a transmission
electron microscope (H-7600; Hitachi High-Technologies). The mice experiments
were not blinded.
Statistical analysis. Statistical analysis was performed with Graph Pad Prism.
One-way ANOVA with Dunnet’s post hoc test was performed. Displayed in the
ﬁgure are the mean values of all technical replicates for each of the independent
experiments. Error bars represent s.d. P values <0.05 were considered statistically
signiﬁcant.
Bioinformatics. Genetic location is according to the February 2009 Human
Genome Browser data (http://www.genome.ucsc.edu).
Data availability. All data generated or analyzed during this study are available in
this published article (and its Supplementary Information Files) or from the cor-
responding author upon reasonable request.
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